Search

Displaying results 4491 - 4500 of 10000 in total
  1. Drug

    Clomethiazole

    go.drugbank.com/drugs/DB06470
    Investigational

    It is a drug which is structurally related to thiamine (vitamin B1) but acts like a sedative, hypnotic, muscle relaxant and anticonvulsant.

  2. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    It was researched in the 1960s and 1970s but never marketed.

  3. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    It was previously marketed in France as Lutionex, but has since been discontinued.

  4. Indication

    Complicated Urinary Tract Infection

    go.drugbank.com/conditions/DBCOND0040639
    Drugs: Cefepime · Cefiderocol · Ceftazidime · Cilastatin · Ciprofloxacin · Doripenem +9 more
    Synonyms: Urinary tract infection, site not specified NOS (disorder), Urinary infection NOS
  5. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  6. Drug

    Dihematoporphyrin ether

    go.drugbank.com/drugs/DB15351
    Investigational

    Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).

  7. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  8. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.

  9. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]

  10. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by … It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily